Adjuvant therapy in resected pancreatic cancer: A systematic review of literature with meta-analysis of randomized clinical trials

Autor: Alessandra Affatato, Lorenzo Gianni, Alberto Ravaioli, Claudio Ridolfi, Luigi Veneroni, Fabrizio Drudi, Gabriele Donati, Davide Tassinari, Federica Carloni, Carlotta Santelmo, Emiliano Tamburini
Rok vydání: 2012
Předmět:
Zdroj: Journal of Clinical Oncology. 30:342-342
ISSN: 1527-7755
0732-183X
DOI: 10.1200/jco.2012.30.4_suppl.342
Popis: 342 Background: To assess the role of adjuvant treatments (AT), adjuvant chemotherapy (AC) and adjuvant chemo-radiotherapy (ACR) in resected pancreatic adenocarcinoma. Methods: A systematic review of literature in the MEDLINE and EMBASE data bases from 1966 to 2011 was independently performed by two authors (FD and DT). All the randomized phase III trials investigating the role of AT in radically resected pancreatic cancer were considered eligible and included into the pooled analysis. 5-year-survival rate in patients treated with AT was the primary end point of the trial, 5-year-survival rate of patients treated with AC and ACR, and the 5-year-survival number needed to treat (NNT) of AT, AC and ACR were the secondary ones. Results: The outcomes of 1402 patients enrolled in 8 trials were compared in the pooled analysis. 816 patients were treated with AT (540 with AC and 276 with ACR), and 586 were enrolled in the control arm (no adjuvant treatment). Significant improve in 5-year-survival rate was observed for AT and AC (odds ratio of 0.636, p2=58%) and AC (I2=31.63%), but not for ACR (I2=0%,). Conclusions: Our data confirm that adjuvant chemotherapy improves the 5-year survival rate in radically resected cancer patients and gemctabine based regimens seem to be better than FU based regimens.
Databáze: OpenAIRE
Externí odkaz: